Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate-binding protein 1 (GBP1) is a large, interferon-inducible GTPase that plays a key role in cell-intrinsic immunity against intracellular pathogens, such as bacteria and viruses[3][4]. Structurally, GBP1 consists of an N-terminal large GTPase domain and a C-terminal helical domain with a CaaX isoprenylation site, which regulates membrane binding. Upon GTP binding, GBP1 undergoes nucleotide-dependent conformational changes, dimerizes, oligomerizes, and forms scaffold-like coats around target membranes—including those of cytosolic bacteria—thus restricting their replication and promoting their clearance[3][4]. GBP1 is regulated by inflammatory cytokines (especially IFNγ), as well as by stress-related transcription factors like p53 and the p38-MAPK pathway[2]. It also regulates cell survival, apoptosis, cytoskeletal organization, and acts as a key modulator of inflammation and cellular stress responses. In tumors, GBP1's role is complex, functioning as both a tumor suppressor and a facilitator of chemoresistance, depending on context[2]. No direct small-molecule drugs currently target GBP1, but its expression is being explored as a biomarker and its pathways may represent future therapeutic opportunities.
GTPase activity (hydrolyzes GTP to GDP and GMP). Oligomerization and membrane coat assembly to encapsulate pathogens. Association with membrane lipids (isoprenylation/farnesylation allowing membrane binding). Regulation via IFNγ pathway, p53, and p38-MAPK.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanylate-binding protein 1 (GBP1).